MetrioPharm Announces Data Presentation on the Mechanism of Action of MP1032 at the 19th SFRRI Meeting in Lisbon
Zurich, May 29, 2018. MetrioPharm AG, a clinical stage pharmaceutical biotech company developing new medications against chronic immune disorders, today announced that preclinical data related to the mechanism of action of the company's lead compound MP1032 will be presented at the 19th biennial Meeting of the Society for Free Radical Research International (SFRRI) in Lisbon.
The poster presentation details are as follows:
- Title: MP1032 - a novel anti-inflammatory drug - ameliorates the progression of autoimmune diseases
- Poster-ID: P-173
- Presented by: Dr. Astrid Kaiser, Head of Drug Development, Dr. Sara Schumann, Project Manager Research and Development
- Date: 5-7 June 2018
- Location: Lisbon Congress Centre
New relevant data on MP1032 and its mode of action will be presented on June 5th by describing a potent scavenging activity of reactive oxygen species (ROS) that leads to site-specific amelioration of inflammatory events. ROS are formed during ordinary metabolism and have important roles in cell signaling. However, adverse stimuli can dramatically elevate ROS production and thereby induce tissue destruction. A dysregulated redox-system with an enhanced ROS production is therefore associated with the development of inflammatory autoimmune diseases including rheumatoid arthritis, multiple sclerosis, and psoriasis.
Dr. Astrid Kaiser explained, "We used a specific technique, the so called ultra-weak photon emission imaging, to monitor ROS production in inflamed joints and demonstrated that MP1032 acts directly and only at the side of inflammation. This is a new and pivotal advantage as many other anti-inflammatory therapies suppress the whole-body immune system and thereby may lead to severe side effects."
Furthermore, the ROS scavenging effect was accompanied by reduced proinflammatory cytokine levels and improved arthritic scores in preclinical models of rheumatoid arthritis. Dr. Sara Schumann commented, "This highlights the therapeutic potential of MP1032 in chronic immune disorders and further supports the good clinical efficacy demonstrated in our human Phase IIa trial with patients suffering from moderate to severe psoriasis".
MP1032 is the lead compound of a class of proprietary immune modulators developed by MetrioPharm. MP1032 is believed to modulate the oxidative stress-mediated activation state of macrophages and downregulate the M1 state. In contrast to other immune-modulating and disease-modifying drugs, MP1032 does not impact T-cells and preferentially affects macrophages at the sites of inflammation. MP1032 has shown anti-inflammatory activity in animal models of disease and a favorable toxicology profile in pre-clinical studies.
MetrioPharm AG is a pharmaceutical biotech company developing drug compounds for the treatment of autoimmune and other inflammatory diseases. MetrioPharm's MP1000 pipeline consists of small molecule immune modulators for unmet medical needs in Immune-Mediated Inflammatory Diseases (IMIDs).
MetrioPharm AG was founded in 2007 and is headquartered in Zurich with research facilities in Berlin.
This press release contains forward-looking statements that involve risks and uncertainties and are consistent with MetrioPharm's assessment as of the date of this release. Such forward-looking statements are neither promises nor guarantees, but are subject to numerous risks and uncertainties, many of which are beyond MetrioPharm's control, that could cause actual results to differ materially from those contemplated in these forward-looking statements. MetrioPharm does not assume any obligation to update forward-looking statements with respect to changed expectations or new events, conditions or circumstances on which these statements are based. A liability or guarantee and, if applicable, claims for topicality, correctness and completeness of these data and information are excluded and cannot be derived either explicitly or impliedly.